Sustained by a recent study that showcased its ability to identify recurrence risk of colon cancer, New York-based molecular diagnostics firm ChipDX is moving ahead with plans to eventually debut at least four microarray-based assays for the clinical market.

CEO Ryan van Laar told BioArray News this week that the two-year-old company currently has in its pipeline tests for colon, breast, lung, and tissue of origin cancer identification.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.